Results 61 to 70 of about 4,708 (131)

The Cost-Effectiveness of Tenofovir Alafenamide for Chronic Hepatitis B Virus in Taiwan

MDM Policy & Practice
Background. Chronic hepatitis B (CHB) is a lifelong disease requiring long-term or indefinite therapy, resulting in substantial economic burden. Thus, careful consideration must be used in the selection of therapies. Aim.
Elise Chia-Hui Tan, Alon Yehoshua, Sushanth Jeyakumar, Pongo Peng, Amy Lin, Nathaniel J. Smith, Nandita Kachru   +6 more
doaj   +1 more source

Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate.

PLoS ONE, 2019
BackgroundBecause tenofovir alafenamide (TAF) leads to significantly lower plasma tenofovir concentrations than tenofovir disoproxil fumarate (TDF) and is a stronger substrate for P-glycoprotein (P-gp) than TDF, TAF could lead to decreased central ...
Linn Hermansson, Aylin Yilmaz, Richard W Price, Staffan Nilsson, Scott McCallister, Tariro Makadzange, Moupali Das, Henrik Zetterberg, Kaj Blennow, Magnus Gisslen   +9 more
doaj   +1 more source

Metabolic Outcomes of Changing From Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine to Rilpivirine/Tenofovir Alafenamide/Emtricitabine: A Longitudinal Study

Health Science Reports
Background and Aims People living with human immunodeficiency virus (HIV, PLWH) are aging, and there are growing concerns regarding combined antiretroviral therapy (cART)‐associated negative metabolic consequences.
Ping‐Feng Wu, Hsi‐Hsun Lin, Hsin‐Pai Chen, Po‐Chieh Huang, Meng‐Yu Ke   +4 more
doaj   +1 more source

Weight Gain in HIV Adults Receiving Antiretroviral Treatment: Current Knowledge and Future Perspectives

Life
Body weight is impacted by several individual host and environmental factors. In a person living with HIV (PLWH), weight is also influenced by the disease stage.
Konstantinos Markakis, Olga Tsachouridou, Eleni Georgianou, Dimitrios Pilalas, Sideris Nanoudis, Symeon Metallidis   +5 more
doaj   +1 more source

Abstracts From AIDS 2026, the 26th International AIDS Conference, 26 – 31 July 2026 Rio de Janeiro, Brazil & virtual

Journal of the International AIDS Society, Volume 29, Issue S4, July 2026.
wiley   +1 more source

Long-term trajectories of hepatic and metabolic biomarkers after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral therapy-experienced people with HIV with and without hepatic coinfection: Data from the ICONA cohort

International Journal of Infectious Diseases
Objectives: Long-term effects of switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) on hepatic, renal, and metabolic parameters remain poorly characterized, especially in people with HIV (PWH) and hepatitis B virus ...
Mariacristina Poliseno, Sergio Lo Caputo, Alessandro Tavelli, Roberta Gagliardini, Lidia Gazzola, Annalisa Saracino, Teresa Antonia Santantonio, Nicola Squillace, Massimo Puoti, Valentina Mazzotta, Adndrea Antinori, Antonella d’Arminio Monforte, Alessandro Cozzi-Lepri   +12 more
doaj   +1 more source

Comparative risk of osteoporosis and fractures in chronic hepatitis B patients: Tenofovir disoproxil fumarate vs. entecavir in a Korean nationwide cohort

JHEP Reports
Background & Aims: The optimal antiviral agent for patients with chronic hepatitis B (CHB) at risk for osteoporosis remains debated. The aim of this study was to compare the incidence of osteoporosis and osteoporotic fractures between patients ...
Yoon E. Shin, Jae Young Kim, Hyuk Kim, Jeong Ju Yoo, Sang Gyune Kim, Young Seok Kim   +5 more
doaj   +1 more source

Switching to Tenofovir Therapy Versus Continuation of Entecavir for Patients With Hepatitis B Virus Infection: A Systematic Review and Meta‐Analysis

JGH Open
Background Hepatitis B virus (HBV) infection causes liver disease, including hepatocellular carcinoma. Controlling viral activity is crucial to reducing complications.
Muhammad Shahzil, Ammad Javaid Chaudhary, Talha Kashif, Ali Akram Qureshi, Anza Muhammad, Faiza Khan, Muhammad Saad Faisal, Muhammad Ali Khaqan, Hassam Ali, Yara Dababneh, Dilip Moonka   +10 more
doaj   +1 more source

First year real life experience with tenofovir alafenamide fumarate: The pythagorean cohort. [PDF]

Hepatol Forum, 2023
Karasahin O, Kalkan IA, Dal T, Toplu SA, Harputluoglu M, Mete AO, Komur S, Sarigul F, Yildiz Y, Esmer F, Kandemir O, Nazik S, Inan D, Akgul F, Kaya S, Tunc N, Bayindir Y, Balin SO, Tasova Y, Aktar F, Oner MM, Ayhan M, Demir Y, Celen MK.   +23 more
europepmc   +1 more source

First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial. [PDF]

Clin Infect Dis, 2023
Waalewijn H, Szubert AJ, Wasmann RE, Wiesner L, Chabala C, Bwakura-Dangarembizi M, Makumbi S, Nangiya J, Mumbiro V, Mulenga V, Musiime V, Monkiewicz LN, Griffiths AL, Bamford A, Doerholt K, Denti P, Burger DM, Gibb DM, McIlleron HM, Colbers A, Children with HIV in Africa – Pharmacokinetics and Acceptability of Simple second-line antiretroviral regimens (CHAPAS-4) Trial Team.   +20 more
europepmc   +1 more source